Cancer fatigue can make everyday tasks exhausting, even after sleep or rest. Learn about possible causes, approaches that may help and symptoms to report to your care team.
Can Keytruda Help When Other Cancer Treatments Stop Working?
CancerSnoop · Treatment News Explained
An option for some patients. A tumor test helps determine who.
An updated US approval supports Keytruda for certain cancers
that have progressed after treatment. The important detail is
a measurable feature of the tumor—not simply whether another
treatment has stopped working.
Can Keytruda help when other cancer treatments stop
working? For some people, yes. But this particular
approval has specific conditions.
[Reference 1]
On October 16, 2026, the US Food and Drug Administration
converted an earlier accelerated approval to traditional approval.
It also raised the required tumor mutational burden, or TMB,
from at least 10 to at least 13 mutations per megabase.
[Reference 1]
What Does That Tumor Test Measure?
TMB describes how many genetic changes are found in a measured
amount of a tumor’s DNA. Think of it as a count of changes,
rather than the name of one particular mutation.
The Term, Explained
“TMB-high” means the tumor meets a defined mutation-count threshold.
For this updated FDA indication, that threshold is
13 or more mutations per megabase, measured
using an FDA-authorized test.
[Reference 1]
Who Does the Updated Approval Cover?
It covers selected solid tumors—cancers growing in tissues or
organs—that cannot be removed surgically or have spread.
The cancer must have progressed after prior treatment, with no
satisfactory alternative treatment options, and meet the TMB
testing requirement.
[Reference 1]
This is a US regulatory decision. Access, approved uses and
payment arrangements must be checked in the country where a
person receives care.
What Did the Study Find?
The FDA’s updated analysis included 220 patients with different
solid tumors meeting the revised threshold.
[Reference 1]
What the Evidence Shows
About 36 out of every 100 patients had a tumor response.
Their tumors shrank enough, or disappeared on assessment,
to meet the study’s response criteria. Among those who responded,
58% had a response lasting at least 12 months.
[Reference 1]
Understanding the Numbers
A response is not the same as a cure.
These figures describe tumor response and how long it lasted.
They do not show that 36% of patients were cured.
The 58% figure applies to people who responded—not everyone
who received treatment.
Why Was the Threshold Raised?
The FDA said efficacy supporting traditional approval was not
confirmed in patients with TMB from 10 to below 13.
[Reference 1]
That is why an older report saying “TMB-high” may need a closer
look. The actual number, test used and clinical setting matter.
This change concerns one indication; it does not describe every
approved use of Keytruda.
Does Keytruda Work the Same Way in Every Cancer?
A pooled result across several cancers should not be read as a
personal prediction. Cancer type and other tumor features still
matter.
A separate 2025 Japanese registry study illustrates this point.
Among pembrolizumab-treated patients with TMB-high metastatic
colorectal cancer, outcomes differed between microsatellite-stable
and microsatellite-instability-high tumors.
[Reference 2]
An Important Limitation
One favorable biomarker does not tell the whole story.
The colorectal study was retrospective, with no random
assignment to treatment. It cannot settle treatment comparisons
or predict an individual outcome. It also did not directly test
the revised 2026 FDA indication.
It supports careful interpretation—not the conclusion that
everyone with a high mutation count will benefit.
[Reference 2]
How Does Keytruda Work?
Keytruda is the brand name for pembrolizumab, a type of
immunotherapy. It blocks a protein called PD-1 on certain immune
cells, helping release a brake on their activity against cancer.
[Reference 3]
It does not simply “boost immunity” in a general way.
Its action affects a specific control system, which helps explain
both its benefits and its risks.
What About Side Effects?
Safety Matters
Immunotherapy can also affect healthy tissues.
Possible effects include fatigue, diarrhea and skin reactions.
More serious problems can involve inflammation of organs,
including the lungs, bowel or hormone-producing glands.
Side effects can occur during treatment or after it ends.
New or worsening symptoms should be reported promptly to
the treating team.
[Reference 3]
Questions to Take to Your Oncology Team
- Has my tumor been tested for TMB?
- What is the exact result, and which test measured it?
-
How do my cancer type and other test results affect
whether Keytruda might help? - What other treatments remain appropriate for me?
- What benefits and side effects should we discuss?
- Is this use approved and accessible where I receive care?
Key Takeaways
-
The updated FDA indication is for selected patients,
not every cancer that has progressed. -
The revised TMB threshold is at least 13 mutations
per megabase. -
The study’s response rate is not a cure rate or a personal
forecast. - Tumor testing and clinical context should guide the discussion.
Read More on CancerSnoop
CancerSnoop Bottom Line
A meaningful option begins with understanding who it is for.
This approval offers a treatment pathway for selected patients.
The next step is a careful conversation about tumor testing,
available alternatives and individual circumstances.
Hope should come with a clear explanation of the evidence.
Sources and Evidence
Reference 1 — FDA regulatory information
FDA grants traditional approval for pembrolizumab or
pembrolizumab and berahyaluronidase alfa-pmph for unresectable
or metastatic TMB-H solid tumors with updated indication.
Decision dated October 16, 2026.
Reference 2 — Observational research
Efficacy of pembrolizumab in microsatellite-stable, tumor
mutational burden-high metastatic colorectal cancer:
genomic signatures and clinical outcomes.
Yamaguchi K, Tsuchihashi K, Ueno S, et al.
ESMO Open. 2025;10(1):104108.
PMID: 39765187.
DOI: 10.1016/j.esmoop.2024.104108
Reference 3 — Patient guidance
Pembrolizumab (Keytruda). Cancer Research UK.
Last reviewed March 24, 2026.
CancerSnoop Note:
Evidence and regulatory information checked October 25, 2026.
This independent educational article does not determine treatment
eligibility or replace advice from an oncology team.
Evidence and regulatory information checked October 25, 2026.
This independent educational article does not determine treatment
eligibility or replace advice from an oncology team.
Continue Exploring
